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Introduction: Seven hundred ninety-five thousand Americans will have a stroke this year,
and half will have a chronic hemiparesis. Substantial animal literature suggests that the
mammalian brain has much potential to recover from acute injury using mechanisms of
neuroplasticity, and that these mechanisms can be accessed using training paradigms
and neurotransmitter manipulation. However, most of these findings have not been tested
or confirmed in the rehabilitation setting, in large part because of the challenges in
translating a conceptually straightforward laboratory experiment into a meaningful and
rigorous clinical trial in humans. Through presentation of methods for a Phase II trial, we
discuss these issues and describe our approach.
Methods: In rodents there is compelling evidence for timing effects in rehabilitation;
motor training delivered at certain times after stroke may be more effective than the
same training delivered earlier or later, suggesting that there is a critical or sensitive
period for strongest rehabilitation training effects. If analogous critical/sensitive periods
can be identified after human stroke, then existing clinical resources can be better utilized
to promote recovery. The Critical Periods after Stroke Study (CPASS) is a phase II
randomized, controlled trial designed to explore whether such a sensitive period exists.
We will randomize 64 persons to receive an additional 20 h of upper extremity therapy
either immediately upon rehab admission, 2–3 months after stroke onset, 6 months after
onset, or to an observation-only control group. The primary outcome measure will be the
Action Research Arm Test (ARAT) at 1 year. Blood will be drawn at up to 3 time points
for later biomarker studies.
Conclusion: CPASS is an example of the translation of rodent motor recovery
experiments into the clinical setting; data obtained from this single site randomized
controlled trial will be used to finalize the design of a Phase III trial.
Keywords: stroke rehabilitation, cerebrovascular disorders, critical period, motor recovery, multi-omics, adaptive
randomization
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Background
Using animal models of stroke, substantial scientific progress
has been made in the understanding of the neural substrates
of recovery after brain injury. Experimental studies of motor
training after injury show that motor function can be improved
significantly when a number of recovery and training variables
are controlled. The experiment of Biernaskie et al. (2004) has
been particularly intriguing given the finding of a sensitive period
after experimental stroke in which rodents are most responsive to
motor training in a specific time window soon after stroke. This
finding has provoked much discussion in the stoke rehabilitation
research community, since of course one wants to rehabilitate
stroke patients at the time after stroke when therapies can be
most effective. In this paper, we discuss the challenges faced
by clinical trialists in translating a conceptually straightforward
rodent experiment into a stroke rehabilitation clinical trial. We
present our methods for the Critical Periods after Stroke Study
(CPASS) as one example of the choices that can be made in
testing whether promising findings in rodents have relevance in
rehabilitation of patients with stroke.
The CPASS trial is designed to translate important findings
from the rodent motor recovery literature into the human clinical
trial setting. Adapting the critical elements of the rodent studies
to the stroke rehabilitation setting requires a series of decisions
and accommodations. In this paper, we review and discuss
these considerations and how we have addressed them. Where
possible we have retained essential elements of the rodent studies,
including manipulation of intervention timing, randomization,
standardized motor training paradigm based on a highly salient
reward, and the use of motor performance measures. Data
obtained from this randomized controlled trial will be used to
formulate more effective treatments to better focus on the needs
of individuals with stroke.
Approaching the Translation of Animal
Experiments into Clinical Trials
Table 1 displays the many advantages of rodent experiments;
these advantages allow exacting study of the biology of
mammalian brain recovery, and the most unequivocal
demonstration of the impact of putative motor training
interventions. The rodents can be healthy young animals
predictably available through breeding or purchase, eliminating
confounds of differences in rearing, medical conditions and
post-injury mortality. The ability to test a group of subjects
simultaneously eliminates any drift in study or training
procedures. Heterogeneity across animal subjects can be limited
by the use of a single gender and a genetically homogenous strain.
Brain lesions can be standardized and made in a brain that is
otherwise pristine. Motor training protocols can be uniform and
timed exactly. Food can be used as a highly motivating reward,
and subjects are not lost to follow-up. Biological mechanisms
can be studied using tissue and molecular techniques requiring
sacrifice of the animals.
Designing a human stroke motor recovery trial tightly linked
to the methods used in rodent motor recovery experiments
involves a series of adaptations. These adaptations attempt to
minimize the real-world limitations of clinical research and to
maximize the clinical and scientific utility. The middle column of
Table 1 displays some of the challenges faced by clinical trialists
as they adapt these experiments to the clinical setting. A simple
direct translation of rodent methods into humans can result in
a trial that would be straightforward to design, but impractical
to execute. For example, an investigator may want to insist that
a single, specific lesion type be present for an individual to
enroll in a clinical trial. This insistence might be scientifically
justifiable, but impossible to execute because of the difficulty of
finding sufficient numbers of individuals who suffered the needed
infarct, meet other inclusion criteria, and are willing and able
to participate in a trial. Similarly, challenges exist in enforcing
exact timing of treatments, the content of treatments, obtaining
motivated participation in training, and simply locating the
individual to collect outcomemeasures. Approaching the biology
of brain recovery in humans is also more challenging because of
the infeasibility of recovering brain tissue; even lumbar punctures
limit large scale participation in trials.
Clinical trial methods can mitigate the limitations of the
stroke rehabilitation clinical setting; many examples are listed
in the third column of Table 1. For example, the problem of
identifying large numbers of participants can be limited through
the use of adaptive trial designs, ensuring that participants will be
randomized only to study arms that are promising. Less stringent
inclusion/exclusion criteria can increase participant accrual, and
the accompanying increase in heterogeneity across subjects can
be managed using adaptive randomization strategies to minimize
differences between study groups. Treatments that begin on a
single preselected day in animals are not realistic in the fluid and
unpredictable clinical setting, but can be replaced by treatment
initiation intervals, allowing flexibility to the participant and
research team. In other cases, investigators must simply make
choices based on knowledge of the population, clinical setting, or
treatment techniques. The number of choices can be quite large,
and often the importance of individual choices is visible only in
retrospect at the end of an expensive multiyear effort to answer
what to all initial appearances is a straightforward question.
Laboratory-based Work in Critical Periods after
Stroke
In current practice, as it becomes possible for the patient to
participate after stroke, rehabilitation begins. This rehabilitation
is initially superimposed on a background of resolving brain
edema, inflammation and apoptosis, which are not thought to
be materially influenced by experiences such as motor training
(Carmichael, 2006; Cramer, 2008).
In contrast, rehabilitation itself is a mixture of compensation
and learning. New learning, particularly that obtained via
activity-based therapies (ABT’s) (Dromerick et al., 2006), is
thought to be accomplished by experience driven neuroplasticity
(Kleim and Jones, 2008; Carter et al., 2010). The patient
relearns prior methods of accomplishing everyday tasks and
when necessary, learns new ways to accomplish goals through
a combination of newly acquired compensatory strategies
(Nakayama et al., 1994) and restoration of motor, sensory, and
cognitive function in uninjured tissues (Lum et al., 2004, 2009;
Frontiers in Human Neuroscience | www.frontiersin.org 2 April 2015 | Volume 9 | Article 231
Dromerick et al. Translating rodent experiments into human trials
TABLE 1 | Issues in translation from rodent experiments to human clinical trials.
Desirable characteristic of rodent experiment
controlled by investigator
Limitations in translation to human subjects Methods to mitigate human subjects
limitations
EXPERIMENTAL SUBJECT POPULATION
• Genetic background
• Rearing conditions
• Subject availability
• Age, gender
• medical comorbidities
• Inexpensive to obtain
• Relatively distant oversight by institutional review
board and animal care committee
• Most human populations genetically
heterogeneous
• Wide variety of socioeconomic and activity
backgrounds
• Enrollment dependent on flow of stroke patients,
and lengthy periods are usually required to identify
and enroll sufficient numbers of participants.
• Close review and oversight by Institutional Review
Boards; heavy documentation required
• Measure important personal characteristics,
analyze as covariates
• Use randomization method to balance for
important subject-specific covariates
• Adjust inclusion/exclusion criteria to minimize
heterogeneity without unduly affecting enrollment
• Adaptive trial designs to ensure participants are
randomized only to promising study arms
• Do studies in large centers with high patient
throughput, or multicenter trials
BRAIN LESIONS
• Defined time of onset
• Reproducible mechanism of injury
• Reproducible lesion location and size
• Injuries occur in otherwise pristine brain
• Muted immunological response to injury
• Quick and relatively complete motor recovery;
greater recruitment of brainstem and
extrapyramidal structures
• Time of onset can be ambiguous
• Multiple stroke mechanisms
• Cause of stroke often undetermined
• Wide variety of stroke lesions
• Prior stroke and white matter changes present
• Greater and more variable immunological
response to injury
• Slower and variable motor recovery
• Use study designs that do not require precise time
of onset (e.g., wide enrollment windows)
• Use randomization method to balance for
important subject-specific covariates
• Use of stratification in design
• Use study designs that do not require specific
stroke mechanisms, or ignore lesions and recruit
based on clinical impairments
• Require specific lesions or lack of background
brain changes
TRAINING CONDITIONS
• Timing
• Amount
• Consistency of training paradigm
• Motivation: High with food rewards
• Little control over timing of patient presentation
acutely, during inpatient or outpatient rehab, or
chronic care setting
• Need to adapt training to clinical environment,
which cannot be controlled by research team
• Need to recruit over months or years can lead to
drift in participant training and assessment
methods
• Amount of training can be dictated by unrelated
factors (insurance, transportation, etc)
• Training is an interaction between unique therapist
and unique participant with specific impairments,
thus difficult to standardize
• Motivation to participate in training program
limited by lack of knowledge about stroke
recovery, cognitive impairment, depression
• Focus study activities at specific clinical
milestones (rehabilitation admission, initiation of
outpatient therapies, etc.)
• Study provides pragmatic support to overcome
insurance payment and transportation barriers
• Treatment protocols that are flexible for participant
needs, but reproducible and well quantified
• Scheduled audits of training protocol execution
and outcome assessment
• Access increased motivation through
patient-centered training activities
BACKGROUND CONDITIONS
• Post-injury environment
• Follow up
• Diet and activity
• Motor training outside of study
• Differences in care across multiple institutions
• Variations in home environment and social support
• Loss to follow up due to subject withdrawal,
moving away, medical events
• Little control over diet
• Little control over therapies prescribed outside of
study
• Recruit from one large institution or standardize
practices across multiple sites
• Measure home environment and social support,
treat as covariate
• Select participants who are socially stable and
unlikely to withdraw or move
• Discourage or prohibit outside therapies as a
condition of study participation; or measure and
treat as a covariate
ABILITY TO STUDY MECHANISM OF RECOVERY
• Sacrifice of subjects for anatomic and metabolic
studies
• Homogenous genetic background
• Brain tissue rarely available
• Cerebrospinal fluid difficult to obtain
• Only non-invasive or minimally invasive
assessments available
• Use of inferential evaluations: multi-omics of
peripheral blood, functional MRI,
electrophysiology
Levin et al., 2009). Since these processes often do not return
the patient back to pre-stroke levels of function, understanding
and exploiting animal findings of critical or sensitive periods in
rehabilitation is an important approach to improving treatment.
These putative periods of greatest responsiveness after stroke
have been hypothesized to be analogous to the “critical periods”
in normal development (Murphy and Corbett, 2009). In the
developing brain, critical periods are defined as times of
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greatest sensitivity to exogenous influences or experiences.
Critical periods for the effect of experience on the formation
of neural circuits and on the behaviors they control have
been demonstrated, for example, in the establishment of
ocular dominance columns and stereopsis in the visual system
(Hubel and Wiesel, 1970), in the formation of attachment
and species identification in a variety of avian species (Hess,
1973), and in vocal learning in songbirds (Marler, 1970) and
in humans (Johnson and Newport, 1989; Newport, 1990). The
molecular mechanisms underlying the opening and closing
of developmental critical periods are beginning to be well
understood (Hensch, 2005), and there are now even examples
of “reopening” early critical periods during adulthood (Bavelier
et al., 2010; Zhou et al., 2011).
The work of Biernaskie et al. (2004) suggests that certain
periods after stroke may constitute a period of enhanced
plasticity, analogous to a critical period during which the
recovering brain is most sensitive to exogenous stimuli and
experience. Thus, there may be an optimal time when stroke
patients might show the largest improvement from therapy; and,
should stroke patients not receive this optimally timed therapy,
it is possible that the opportunity for optimal recovery could
be irrevocably lost. Given the discontinuities in US health care,
it is common for patients’ therapy to be delayed for personal,
medical or insurance reasons (Ostwald et al., 2009); even
inpatient rehabilitation admission does not guarantee substantial
amounts of motor training (Lang et al., 2009). Carefully executed
studies demonstrating the optimal timing of therapies will
help clinicians and policymakers ensure delivery of effective
rehabilitation.
Most of the evidence regarding the timing effects of post-
stroke motor training focuses on the behavioral, cellular, and
molecular mechanisms of neuroplasticity. More recently, animal
models demonstrate that genes involved in normal development
(and that are quiescent in adulthood) are expressed at high
levels in the first weeks after stroke and then decline, with
distinct temporal patterns of gene expression after injury
(Carmichael, 2003, 2006). This pattern of gene expression is
consistent with the notion of an injury-induced recapitulation
of development-like processes which occur during a period of
enhanced plasticity. Most of these findings focus on the first
weeks after stroke; our study design has three relevant time
points (early/acute, subacute, and chronic), in order to best
assess and locate such an effect, if indeed it occurs in human
patients.
There are two major findings regarding treatment timing
in animal models of stroke. First is the work of Schallert
(Kozlowski et al., 1996; Humm et al., 1998) and others (Bland
et al., 2000) showing that very early and intensive training can
reduce recovery after experimental stroke and enlarge lesions.
This may have been confirmed in humans in our own work
(Dromerick et al., 2009), when we found that very intense
motor training early after stroke led to worse outcomes. Second,
and more optimistic is the work of Biernaskie et al. (2004)
where the question of timing effects was directly addressed.
They randomized lesioned animals to receive focused motor
training at 5, 14, or 30 days after lesioning. They found that
the best response to training started at 5 days after lesioning; an
intermediate response was present when training was initiated
at 14 days; and therapy beginning at 30 days resulted in the
same motor outcome as controls who were not trained at all.
This powerful pattern of results suggests that critical periods in
stroke recovery do exist in adult mammals (Murphy and Corbett,
2009).
Human and Clinical Data regarding Timing
Effects in Rehabilitation Treatment
Whether and how the results of Biernaskie et al. translate to
human stroke patients is unknown. Few prospective human
studies directly address optimal timing of rehabilitation. Natural
history studies show that recovery after stroke in humans is
fastest in the first weeks (Wade and Hewer, 1987; Jorgensen
et al., 1995a,b); this period coincides with both the onset of
rehabilitation treatment and the time that homeostasis is re-
established, as described above. Clinicians have written for
decades regarding the features of motor recovery that seem
to resemble patterns of normal motor development (Cramer
and Chopp, 2000; Pollock et al., 2007; Kollen et al., 2009).
Retrospective data from clinical populations suggest that early
initiation of rehabilitation is associated with better outcome
(Wylie, 1970; Feigenson et al., 1977; Kotila et al., 1984; Rossi
et al., 1997). However, these studies are confounded because
patients who present late to rehabilitation are generally sicker
and more severely affected, and thus less likely to improve
regardless of timing of care (Ween et al., 1996). Some,
but not all (Gagnon et al., 2006) newer studies using case
control methods (Paolucci et al., 2000) or large multicenter
cohorts (Maulden et al., 2005) have also found better responses
early.
Secondary analyses of existing clinical trials are mixed. The
EXCITE trial (Wolf et al., 2006) evaluated whether constraint
therapy was superior to an uncharacterized “usual and customary
care” (UCC) control in improving UE motor impairment;
secondary analyses suggested that the participants treated earlier
had a better motor outcome than those treated later (Wolf
et al., 2010). The LEAPS trial (Duncan et al., 2011) of body-
weight supported treadmill training for gait did not confirm a
timing effect. LEAPS found that there were persistent treatment
responses at both time points tested (2 and 6 months), but
there were no significant outcome differences between the earlier
and later groups. VECTORS, a single center Phase II trial
(Dromerick et al., 2009) of constraint therapy early after stroke
addressed dosing and therapy content rather than timing, but
the results at this earlier time period suggested an inverse
dose response relationship (at high doses, more therapy led to
less motor recovery). A more recent study testing additional
rehabilitation therapy early after stroke did not confirm this
inverse dose phenomenon and suggested greater ipsilesional
cortical activation on functional MRI in those randomized to
extra therapy (Hubbard et al., 2014). A recent trial in ICH
patients suggested a possible mortality benefit with early therapy
(Liu et al., 2014). Preliminary data fromAVERT (Bernhardt et al.,
2008), an early mobilization RCT, are promising but enrollment
is still ongoing.
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Study Rationales and Hypotheses
The overall goal for the CPASS trial is to identify a critical period
after stroke in which patients are particularly responsive to motor
training interventions. We hope simply to elicit a signal that a
critical period exists; optimization of dosing or treatment strategy
would come in subsequent studies.
Our approach is to use a bolus of standardized motor therapy
to elicit a motor improvement during a specific time period
indicative of a critical period. Our hypothesis for the CPASS
Phase II trial is that, compared to individuals randomized to
the control condition or to the subacute (2–3 months after
onset) or chronic (6–9 months after onset) time points, persons
randomized to early intensive motor training will show greater
UE motor improvement measured at 1 year. In addition, we
will use the opportunity presented to collect peripheral blood
to perform a proof of principle study exploring molecular
signals associated with response to treatment and overall motor
recovery. See Figure 1 for a diagram of study design.
In order to adapt the rodent experimental design to the
clinical delivery patterns in the United States, we made two
major decisions. First was the choice of time periods in which
study-related treatment would be delivered. Precisely how post-
stroke days compare between humans and rodents is unknown,
and we attempted to balance fidelity to the Biernaskie et al.
design with the pragmatics of accommodating existing treatment
venues. These venues are not under the control of the research
team. Choosing the exact time points and a single day window
to initiate therapies such as was used in the rodent study meant
that participants would need to be consented within 72 h of
stroke onset so that baseline measures could be collected and
the participant randomized with the possibility of treatment
beginning exactly on post-stroke Day 5. Though conceptually
not impossible, this choice would lead to several complexities
including unavailability of patients to undergo study related
therapy during a time when diagnostic testing must take first
priority, medical complications and fatigue preventing therapy
participation, uncertainty about the trajectory of motor recovery,
and uncertainty as to whether and where the patient might
be referred for inpatient rehabilitation. We chose instead three
more flexible windows of time for study related treatments: early
(<30 days, corresponding to the inpatient rehabilitation period),
subacute (60–90 days, corresponding to typical outpatient
therapy delivery), and chronic (6 months, by which timemost US
stroke patients will have been discharged from therapy). These
times were chosen as analogous to the 5, 14, and 30 day times
used in the Biernaskie et al. study. By using those existing clinical
treatment venues, any improvements in efficacy that results from
this line of work can improve the effectiveness of those venues
without requiring a major change in how care is delivered. Thus,
the translation to actual treatment would not be hindered by the
need for policy and reimbursement changes.
The secondmajor decision was that of howmuch study related
treatment was necessary to observe a detectable effect of a critical
period. Dose-response data for motor training are particularly
lacking in the first few weeks after stroke onset. We chose 20 h
of additional motor therapy because our previous work has
shown that a difference of 10 h of treatment is sufficient to
alter motor outcomes; this amount of additional therapy should
thus provide an adequate signal indicating a critical period, if
there is one (Dromerick et al., 2009). Moreover, should we find
a large difference in outcomes in one group, it seems feasible
FIGURE 1 | Study design. Baseline assessment (T1) occurs within the
first month following stroke and subjects are randomized to one of four
groups: early—additional 20 h of occupational therapy (OT) initiated <1
mo. from stroke onset, subacute—additional 20 h of OT initiated 2-3 mo.
from stroke onset, chronic—additional 20 h of OT initiated 6-7 mo. from
stroke onset, and control—no additional OT. All subjects are reassessed
at 1 year (T2) to evaluate for durable change in study-related outcome
measures.
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to deliver 20 h more training to stroke patients in the current
healthcare environment. Several studies document persistent
motor improvements post-stroke with treatments of similar or
even less intensity (Sivenius et al., 1985; Sunderland et al., 1992;
Whitall et al., 2000; Page et al., 2001; Michaelsen and Levin, 2004;
Michaelsen et al., 2006; Woldag et al., 2010; Han et al., 2013).
Methods
Patient Population
Sixty-four participants will be recruited primarily from the
inpatient stroke service at MedStar National Rehabilitation
Hospital (MedStar NRH). MedStar NRH hosts the Washington
DC site for the NINDS StrokeNet, and recruitment from other
DC area hospitals can be used if needed. Study participants will
include adults with neuroimaging confirmed diagnosis of recent
ischemic stroke or intraparenchymal hemorrhage. SeeTable 2 for
a comprehensive list of inclusion/exclusion criteria.
Study Measures
The primary outcome measure, secondary outcome measures,
and covariates are listed in Table 3 along with the time periods
at which they will be assessed. Pre-treatment, 6 mo, and
1 yr assessments will be performed by study therapists and
the assessments for the motor scales will be videotaped. A
blinded therapist will view the videotapes to provide the formal
assessments for each subject at the end of the study, including the
ARAT primary outcome measure.
Further information on study outcome measures and
covariates are provided below:
• Action Research Arm Test (ARAT): The ARAT, adapted
from the Fugl-Meyer (Fugl-Meyer et al., 1975), assesses
functional limitations of the UE and is the primary outcome
measure for the study. It uses a 4-point ordinal scale on
19 items, where 0 indicates no movement and 3 indicates
normative movement. The scale has 4 subscale scores- gross
motor (9 point maximum), grasp (18 point maximum), grip
(12 point maximum), and pinch (18 point maximum)- and a
total scale score with a maximum of 57. The ARAT has been
shown to be reliable, valid, and responsive to change across
a variety of time points post-stroke (Deweert and Harrison,
1985; Hsieh et al., 1998; Van der Lee et al., 2001, 2002; Lang
et al., 2006).
• Motor Activity Log (MAL): The MAL is a 28-item
questionnaire measuring UE use on functional tasks
(Uswatte et al., 2006; Taub et al., 2011). It has two subscales:
Amount of Movement (AoM) and Quality of Movement
(QoM).
• Nine Hole Peg Test: The nine hole peg test measures
bimanual dexterity. The test assesses the amount of time
required to position and remove nine (9) pegs on a board
(Mathiowetz et al., 1992).
• Functional Independence Measure (FIM): The FIM assesses
18 item activities of daily living (Granger et al., 1993). Two
subscores are created: a motor score and a cognitive score.
Subscales will be analyzed separately.
• Motor Assessment Scale: The Motor Assessment Scale is
a test which assesses an individual’s supine to side lying,
supine to sitting edge of bed, balanced sitting, sitting to
standing, walking, upper-arm function, hand movements
and advanced hand movements (Carr, 1992). For this study
the upper-limb function portion of this test will be utilized.
• Barthel Index: The Barthel Index is the most commonly used
measure of functional performance in stroke clinical trials
(Shah et al., 1989).
• Upper Extremity Fugl-Meyer (UE-FM): The Fugl-Meyer will
be used to assessmotor function at the shoulder, elbow, wrist,
and fingers (Fugl-Meyer et al., 1975). It scores reflexes and
the ability to perform several simple movements and tasks
on a 3-point scale. Validity and reliability of the Fugl-Meyer
TABLE 2 | Inclusion/exclusion criteria.
Inclusion criteria
1. Ischemic or hemorrhagic stroke (with confirmatory neuroimaging) within 28
days of admission to inpatient rehabilitation.
2. Age >21 years
3. Able to participate in first study-related treatment session within 30 days of
stroke onset.
4. Able to participate in all study-related activities, including 1 year follow up and
blood draws.
5. Persistent hemiparesis leading to impaired upper extremity function as
indicated by a score ≥1 on the NIHSS motor arm score, AND motor
impairment judged clinically appropriate as defined by one or both of the
following:
a. Proximal UE voluntary activity indicated by a score of ≥3 on the upper arm
item of the motor assessment scale; wrist and finger movement is not
required. OR
b. Manual muscle test (MMT) score of ≥2 on shoulder flexion and either elbow
flexion or extension.
6. Score of ≤8 on the short blessed memory orientation and concentration scale
7. Follows 2 step commands
8. No upper extremity injury or conditions that limited use prior to the stroke
9. Pre-stroke independence: modified rankin score 0 or 1
Exclusion criteria
1. Inability to give informed consent
2. Prior stroke with persistent motor impairment or other disabling neurologic
condition such as multiple sclerosis, parkinsonism, ALS, dementia requiring
medication
3. Rapidly improving motor function
4. Clinically significant fluctuations in mental status in the 72 h prior to
randomization
5. Hemispatial neglect as determined by an asymmetry >3 errors on the
mesulam symbol cancellation test.
6. Not independent prior to stroke (determined by scores of <95 on barthel
index or >1 on modified rankin scale
7. Dense sensory loss indicated by a score of 2 on NIHSS sensory item
8. Ataxia out of proportion to weakness in the affected arm as defined by a
score ≥1 on the NIHSS limb ataxia item.
9. Active or prior psychosis within 2 years
10. Active or prior (within 2 years) substance abuse
11. Not expected to survive 1 year due to other illnesses (cardiac disease,
malignancy, etc)
12. Received UE botulinum toxin within 6 months. (other meds do not exclude)
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TABLE 3 | Study measures and covariates.
Measure Domain measured Baseline Pretreat Post-treat 6 Mo 1 Yr
Action research arm test Motor functional limitation (performance) x x x x x
Motor activity log Motor disability (self-report) x x x x x
Nine hole peg test Motor functional limitation x x x x x
Functional independence measure ADL disability x x x x x
Motor assessment scale UE motor functional limitation x
Barthel index ADL disability x x x x x
Fugl-meyer upper arm Motor functional limitation (performance) x x
Manual muscle test Motor strength and function x
Motricity index x x x x x
Stroke impact scale-perception of change Stroke-specific quality of life x x x x
Stroke impact scale hand-arm subscale Stroke-specific quality of life x x x x
Modified Rankin Scale Handicap/Global outcome x (prestroke) x x x
Activity card sort Participation x x x x
Reintegration to normal living Participations x x x
Geriatric depression scale Depression screen/covariate x x x
NIH stroke scale Stroke severity x x x x
Short blessed orientation memory concentration test Dementia screen x
Mesulam symbol cancellation test Visuospatial neglect x x x x
Faces scale Pain (visual analog) x x x x x
Medication inventory Covariate (recovery-modifying drugs) x x x x x
Charlson comorbidity index Covariate (medical complexity) x
Oxfordshire classification Covariate (lesion type) x
Edinburgh inventory Covariate (handedness) x
Age Covariate x
Test have been established (Lin et al., 2009). The Fugl-Meyer
was designed for the recovery patterns observed after stroke
and is most sensitive to detecting changes in subjects with
moderate to severe impairment.
• Manual Muscle Test (MMT): The Manual Muscle Test
evaluates strength and function of individual muscles to
assess the degree of muscular weakness resulting from injury
or disease (Medical Research Council, 1976). The therapist
palpates each muscle while the subject voluntarily contracts
the muscle against resistance. A score ranging from 0 to 5
indicates the relative strength.
• Motricity Index: The Motricity Index is a short and simple
measure of motor loss primarily developed for use after
stroke (Collen, 1992). This measure has proven validity and
reliability and is sensitive to change in motor function after
stroke.
• Stroke Impact Scale (SIS): (SIS Hand Function Subscale
and SIS Recovery Scale): The SIS is a self-report scale
for evaluating stroke recovery (Duncan et al., 1999).
The 5-item Hand Subscale assesses hand strength,
dexterity, fine, and gross motor ability associated
with the ability to complete functional tasks. In the
Recovery Subscale, the patient is asked to assess his or
her overall degree of recovery; possible scores range
from 0 to 100 with higher scores indicative of better
outcomes.
• Modified Rankin Scale (mRS): The mRS measures the
degree of disability and level of independence in those
who suffer from neurologic injury (van Swieten et al.,
1988). In addition to serving as a secondary outcome
measure, the mRS will be used to gauge pre-stroke level of
disability.
• Activity Card Sort (ACS): The ACS is a self-report measure
of activity in four domains: instrumental activities, high and
low physical-demand leisure activities, and social activities
(Baum and Edwards, 2008).
• Reintegration to Normal Living: This 10 item Likert
scale evaluates life satisfaction and quality of life
(Stark et al., 2005).
• Geriatric Depression Scale: The 5 items version of the
Geriatric Depression Scale will be used to screen for
depression (Yesavage, 1988).
• NIH Stroke Scale (NIHSS): The NIHSS assesses cognitive,
sensory, and motor impairments as an indicator of overall
stroke severity (Brott et al., 1989).
• Short Blessed OrientationMemory Concentration Test: This
test screens for dementia by assessing orientation, reasoning
and short-term memory (Katzman et al., 1983).
• Mesulam Symbol Cancellation Test- This paper and pencil
measure uses a cancelation task to assess visuospatial neglect
(Mesulam, 1985). More than 3 omissions between the left
and right visuospatial field indicates neglect.
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• Pain Scale: A scale with cartoon faces that represent varying
degrees of pain. The subject is asked which face reflects their
current pain level (Wong et al., 2001).
• Charlson Comorbidity Index: An index that factors in
a subject’s medical comorbidities and age to derive a
probability of 10 year survival (Charlson et al., 1987).
• Oxfordshire Classification: Classifies stroke based on
neuroimaging/clinical data according to 4 possible stroke
locations/severities: total anterior circulation stroke, partial
anterior circulation stroke, posterior circulation stroke, and
lacunar stroke (Mead et al., 2000).
• Edinburgh Inventory: A questionnaire that determines the
degree to which a subject is left- or right-handed (Oldfield,
1971).
Procedures
The trial was approved by the Institutional Review Board
at MedStar National Rehabilitation Hospital/MedStar Health
Research Institute (protocol #2014-065). All study subjects will
provide informed consent prior to engaging in study procedures.
Based on recruitment rates for the ICARE trial (Winstein et al.,
2013), which was conducted at the same hospital and had
somewhat similar inclusion/exclusion criteria, we anticipate all
subjects for CPASS will be recruited by the end of year 2 and final
outcome measures will be collected by the end of year 3.
Randomization
The approach to randomization offers an opportunity to mitigate
some of the limitations of stroke rehabilitation clinical trials.
Specifically, randomization allows the investigator to decrease
the impact of heterogeneity of important personal characteristics
among subjects that could affect the overall study results. Ideally,
all important and measurable characteristics could be balanced
across the study, but there are limits to the number of variables
that can be balanced, short of enrolling a sample far larger
than circumstances permit. To avoid groups that are unbalanced
with respect to potentially important secondary variables, we
use an adaptive randomization strategy based on methods
described by Atkinson (1982), Meinert (1986), and Signorini
et al. (1993). The adaptive randomization scheme (Yuan et al.,
2014) that we have developed increases to six the number of
variables that can be balanced in this sample of 64 subjects.
We have chosen to balance these variables that we have judged
to be most important: age, number of days from stroke onset
to baseline evaluation, ischemic vs. hemorrhagic stroke type,
baseline ARAT score, concordance (dominant vs. non-dominant
UE affected) and overall stroke severity as indicated by NIHSS
score at baseline evaluation. We were limited to six variables to
balance; we prioritized these over other potentially important
variables such as the presence of a fully recovered prior stroke in
the randomization. Cortical involvement was another potential
randomization variable that we chose not to address because
neuroimages are not always available at our center, and resources
did not allow for study-related imaging. By balancing days from
stroke onset to baseline evaluation, we minimize the impact of
variability of time from onset to rehabilitation admission.
Interventions
In designing the motor training intervention for CPASS, we
addressed several goals for mitigating the limitations of clinical
trials. These included motivating subjects as well as developing a
standard treatment approach that is theory driven, measurable,
and reproducible. Ideally, the treatment should be engaging
and meet the clinical goals and interests of the individual
participant.
One important advantage of rodent studies over human trials
is the ability of the investigator to motivate maximal engagement
and participation by study subjects. Rodent and human motor
training paradigms are based on the work of Thorndike who
proposed the “law of effect” (Thorndike, 1898). The law of
effect suggests that responses closely followed by satisfaction
will become firmly attached to the situation and therefore will
be more likely to recur when the situation is repeated. This
principle forms the basis of operant conditioning (Skinner, 1938).
Operant conditioning experiments of motor training in rodents
have shown that food is a powerful form of reinforcement in
motor learning studies. Studies demonstrated that food pellets
as positive reinforcers produced more rapid motor learning and
better retention of learned responses than foot shocks as negative
reinforcers in rodents (Lawson and Watson, 1963). Animals
receiving highly desirable food pellets learned faster and retained
more than those who were reinforced with minimally acceptable
pellets. These principles form the foundation of the translation
of rodent models of stroke recovery to the present treatment
protocol: the use of highly salient reinforcement procedures to
reinforce motor training activities.
In a human clinical trial, the use of delayed feeding and
food rewards to increase motivation is not feasible. Instead,
we developed an individualized treatment protocol based on
the UE functional activity preferences of study participants. To
standardize the elicitation of an individual participant’s preferred
activities, we used a widely accepted measure of leisure and
functional activities. Sixty-five functional activities requiring
upper extremity performance assessed by the Activity Card Sort
(ACS) (Baum and Edwards, 2008) minus 24 of those activities
that do not involve upper extremity involvement are presented
during the treatment-planning phase in order to identify pre-
stroke social, instrumental, high and low demand leisure UE
activities. Study participants are asked to identify and rank
the 10 most important activities that require arm and hand
skills that they want to focus on during their treatment. Study
participants are also able to add activities not included in the
ACS. Participants rank the importance of each activity. Study
therapists use these activities to develop a specific treatment plan
based on a series of shaping tasks that are described below.
These tasks are used for the treatment of all participants. Thus,
there is customization for the goals and priorities of individual
participants, but uniformity of actual motor training using the
library of shaping tasks. All study participants will receive their
usual and customary care (UCC) treatment as prescribed by
the clinical team and approved by their insurance company.
Data are collected on the number and type of UCC therapy
sessions, but no attempt will be made to standardize UCC.
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Study related therapies will be delivered by research-employed
certified physical or occupational therapists; the study team
meets twice weekly to review treatment related issues and insure
reproducibility.
Persons randomized to the early group (<30 days) have
study-related treatments started as quickly as possible; those
randomized to a later time point will have their treatment
started as close as possible to the first day of their treatment
window (2 mo. or 6 mo. post-stroke for the subacute and
chronic groups respectively). By concentrating therapy for the
early group as much as feasible, overlap with the subacute group
will be minimized or eliminated. Study related treatments will
be delivered in addition to UCC, and will consist of 20 h of
therapy delivered in 10 two-hour sessions 2-3x/week. In the
United States, stroke patients admitted to the acute inpatient
rehabilitation setting are generally required to receive 3 h of
therapy daily; however a multisite study (Lang et al., 2009)
demonstrated a paucity of time devoted to restorative motor
training that was remarkably consistent at less than 10min
daily. Thus, the additional study-related training overwhelms
any differences in the amount of UCC training delivered to
individual study participants. To avoid reproducing the High
Intensity condition used in the VECTORS trial, individuals
randomized to the early/acute group will only receive 1
additional hour of treatment per session until discharge from
in-patient rehab, and then will receive 2 h of treatment per
session similar to the subacute and chronic groups. This
training will focus exclusively on UE motor training, and
the use of the more affected UE in the activities identified
by the baseline. This treatment will be delivered in the
inpatient rehab setting (for those randomized to the early
group) or outpatient clinic settings (for subacute and chronic
groups) whenever possible. If needed, the study therapy will
be provided in the home to achieve the requisite 20 h of
treatment.
Balancing the need to customize study-related treatment to
the goals and preferences of individual participants (thereby
maximizing motivation) while at the same time delivering a
measurable, reproducible, and theory driven motor training
program is important. The shaping treatment developed for
use in VECTORS, an NINDS-funded Phase II trial (Dromerick
et al., 2009) will be included in the 20 h of therapy. Constraint
will not be used. Shaping is a process used in both human
and rodent motor training after stroke. There are many
theories of why shaping produces lasting changes in motor
performance (Taub et al., 1994; Ingvaldsen, 1997; Winstein
et al., 2013). The selection of tasks is very important since the
participant must be committed to achieving the goal despite the
difficulty of task performance. The therapist grades the tasks to
provide enough challenge to encourage progress while guarding
against frustration and failure which act as negative reinforcers
and decrease the probability of full participation in the
treatment program. The therapist offers positive reinforcement
in the forms of verbal and visual feedback. Task difficulty is
increased when the participant completes two sets of 10 correct
repetitions of task performance on two consecutive days of
treatment.
Statistical Analysis
Power analysis estimated that a sample size of 64 (16 per study
arm) is sufficient to test the study hypotheses based on the
standard deviations and treatment differences observed in the
VECTORS trial. The study sample size is determined based on
demonstrating a moderate effect size (0.425 as observed in the
preliminary data) in the primary endpoint, the ARAT at 1 year in
an ANOVA model, with 80% power at a significance level of 5%.
The specific comparison of the treatment at each time point will
be conducted using contrasts. One interim analysis is planned
when the number of patients with 1 year ARAT reaches 32.
This analysis following the adaptive group sequential procedure
allows us the opportunity to spot treatment time points with
pronounced improvement in ARAT or the lack thereof while
maintaining the rigor (e.g., Type I error) of the trial.
The general linear model (ANOVA) will be used for group
comparisons on the primary endpoint ARAT using intent to treat
principle. All subjects recruited into the study will be included in
this primary analysis except the run-in participants. Additional
per protocol secondary analyses will be performed. The timing
of treatment hypothesis will be addressed by contrasts between
the four treatment groups at 1 year after stroke. The magnitude
of these effects will be computed. The analysis on secondary
endpoints will be mostly descriptive in nature given the limited
sample size in this pilot trial.
We will also examine additional covariates to ascertain which,
if any, of these covariates are correlated with treatment response,
we will carefully examine the data for indications of interactions
between covariates and treatment effects. Cross validation for
the selected covariates predictive of patient outcome will be
performed. Such covariates will then be considered as potential
exclusion criteria for future trials of therapy dosing during
identified sensitive periods after stroke.
Analysis of the motor function measures and their correlation
with clinical scales of UE motor function will allow us to select
the particular parameters to be retained in future trials should a
sensitive period be found. If the effects are large, a subsequent
trial can be designed in a more economical fashion.
Data obtained from the skill and activity rankings will be
analyzed using Spearman rank coefficients. Skill preference
scores per category will be calculated by summing the total
preference scores belonging to a specific skill category. Overall
satisfaction scores will be computed for the selected skills
following the standard scoring procedures established for the
Motor Activity Log. These summed scores will be analyzed using
appropriate parametric or non-parametric repeated measures
analyses based on the distribution of the scores. The correlative
analysis with multi-omic assessments is more descriptive given
the limited sample size and is described further in the next
section.
Peripheral Blood Draws for Multi-omic
Assessments
The CPASS trial also presents an opportunity to determine
whether the samemolecular processes that occur in experimental
animals post-stroke also take place in the human. The last decade
has produced an explosion in the analytic methods used to
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assess various clinical specimens. Blood biomarker analysis in
human stroke is not new, but most of the focus up to this
point has remained in the hyperacute phase—finding biomarkers
to diagnose acute stroke (Tang et al., 2006). Blood biomarker
analysis is viable because many brain-derived molecules cross
the blood-brain-barrier, including micro-RNA’s, lipids, short
peptide chains, and exosomes. Based on similar analyses from
relevant conditions such as TBI (Diaz-Arrastia et al., 2014) and
Alzheimer’s Disease (Mapstone et al., 2014), we believe there is a
reasonable expectation of useful molecular signals. Additionally,
it seems possible that peripheral metabolism might also affect
recovery.
In order to limit sample variability in the CPASS trial,
whenever possible, blood draws will be performed on fully
awake subjects, between 8 a.m. and 10 a.m., who are fasting
at least since midnight, and have not yet taken their morning
medications. Multi-omic analyses requires collection of blood
into three lavender top (EDTA) tubes (7ml) and three PAXgene
tubes (2.5ml), which are processed and stored for later analysis at
study conclusion. To minimize costs and subject burden, we will
limit blood draws to baseline, pre-treatment, and post-treatment
assessments.
Multi-omics Analysis from Peripheral Blood
Specimens
We plan to use a variety of methods in analyzing human blood
specimens from subjects in the CPASS trial. In this article we will
use the term multi-omics to represent what some call panomics
or “pan-omics,” terms used to identify a group of molecular
biological methods and technologies, including metabolomics,
proteomics, transcriptomics, epigenomics, genomics, and
exosomics. While each of these methods has the potential
to provide important insights, integration of their combined
analytic results may further elucidate the biological basis of
human stroke recovery.
To our knowledge, there are no completed studies testing
multi-omics approaches during the recovery phase of human
stroke. We know of two studies currently underway: the START
trial (Carey et al., 2013), which seeks to identify a gene profile
for post-stroke depression; and BAPTISe (Nave et al., 2013),
which looks for changes in specific lipids and proteins related to
post-stroke cardiovascular training. Our approach to molecular
analysis in CPASS differs in many ways. In CPASS, we seek
to identify profiles of differentially expressed genes, lipids, and
proteins in the baseline blood draw that will distinguish those
with good recovery from those with poor recovery at 1 year.
In addition, we will compare blood samples drawn immediately
before and after the 20 h of additional OT in the subacute and
chronic groups with the hope of identifying molecular changes
associated with OT. Given the small number of subjects in
each group (16), omics findings for therapy-related changes will
largely be descriptive in nature. Similar to START, but unlike
BAPTISe, we will take an untargeted approach to multi-omics.
In other words, we will not identify particular genes, lipids, and
proteins a priori, but rather will use advanced bioinformatic
techniques to identify candidate biomarkers. Our past experience
suggests this untargeted approach is an effective method to
identify novel biomarkers in neurologic disease (Mapstone et al.,
2014). Another important way in which our analysis differs is that
it will include exosomics. Exosomes are small vesicles released by
almost all cell types including neurons. Central nervous system
(CNS) exosomes appear to exit to the periphery and comprise
at least 10–20% of plasma exosomes (Fiandaca et al., 2014). We
anticipate that the analysis of protein, lipid, and RNA cargos
from the CNS-derived exosomes in plasma may allow us to
differentiate biological changes taking place in the CNS from
those occurring in the periphery during stroke recovery.
Discussion: Challenges of Translating an
Animal Experimental Paradigm into a
Human Clinical Trial
Laboratory experiments using rodents have many advantages
that allow the most exacting study of the biology of mammalian
brain recovery, and the most unequivocal demonstration of the
impact of putative motor training interventions. At the same
time, the application of the scientific findings uncovered in
the laboratory is motivated in large part by improving brain
injury recovery in humans. For the translation of rodent findings
to human disease, demonstration that the findings in rodents
generalize to humans is essential, and requires clinical trials. We
have designed a human stroke motor recovery trial tightly linked
to the methods used in rodent motor recovery experiments done
in the laboratory. Our design decisions have been made with the
goals of minimizing the real-world limitations of rehabilitation
trials and maximizing the clinical and scientific utility of our
efforts and those of our study participants. A single center trial
allows for maximal control of experimental conditions, but that
control cannot approach that of a rodent laboratory.
The CPASS trial lays the groundwork for determining
whether critical periods truly exist following human stroke. This
phase II trial will provide the necessary data to conceive a
well-planned definitive multicenter trial. The CPASS trial will
navigate the challenges of delivering study-based occupational
therapy in three different settings: during inpatient rehabilitation,
outpatient rehabilitation, and in the patient’s home. Bymeasuring
the primary endpoint at 1 year, we ensure that any treatment
related difference between groups is durable—a key feature if
we are to prove the existence of a critical period. Elucidation
of molecular markers for recovery might lead to lab tests that
could identify sensitive periods, when persons with stroke can
best use treatment resources to achieve their goals. This could
also someday lead to drug development that could prolong or
restore sensitive periods during stroke recovery, giving persons
with stroke a better recovery and thus more opportunity
to choose goals and more fully participate in society. We
hope that the advances explored by CPASS will lead to new
discoveries in the field and ultimately better outcomes for stroke
patients.
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